Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg

NCT00701363 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00701363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00701363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, International, Multi-centric, Open-label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on the Long Term Treatment With Octreotide LAR 10 or 20 mg
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2008
Completion date
May 31, 2013
Enrollment
124 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly